Capital Asset Advisory Services’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $516K | Buy |
3,800
+127
| +3% | +$17.8K | 0.02% | 185 |
|
|
2025
Q4 | $446K | Buy |
3,673
+101
| +3% | +$12.3K | 0.02% | 189 |
|
|
2025
Q3 | $397K | Buy |
3,572
+362
| +11% | +$41.1K | 0.02% | 202 |
|
|
2025
Q2 | $359K | Sell |
3,210
-384
| -11% | -$40.9K | 0.02% | 206 |
|
|
2025
Q1 | $402K | Sell |
3,594
-410
| -10% | -$42.3K | 0.02% | 189 |
|
|
2024
Q4 | $366K | Buy |
4,004
+367
| +10% | +$33K | 0.02% | 222 |
|
|
2024
Q3 | $310K | Buy |
+3,637
| New | +$278K | 0.02% | 247 |
|
|
2024
Q1 | – | Sell |
-3,904
| Closed | -$316K | – | 323 |
|
|
2023
Q4 | $316K | Sell |
3,904
-1,442
| -27% | -$112K | 0.02% | 235 |
|
|
2023
Q3 | $411K | Sell |
5,346
-89
| -2% | -$6.85K | 0.03% | 215 |
|
|
2023
Q2 | $420K | Sell |
5,435
-380
| -7% | -$30.3K | 0.03% | 219 |
|
|
2023
Q1 | $482K | Sell |
5,815
-1,193
| -17% | -$98.8K | 0.04% | 209 |
|
|
2022
Q4 | $622K | Sell |
7,008
-1,224
| -15% | -$96.9K | 0.05% | 177 |
|
|
2022
Q3 | $508K | Sell |
8,232
-2,062
| -20% | -$130K | 0.07% | 165 |
|
|
2022
Q2 | $636K | Buy |
10,294
+1,278
| +14% | +$79.1K | 0.07% | 195 |
|
|
2022
Q1 | $536K | Buy |
9,016
+206
| +2% | +$13.2K | 0.06% | 241 |
|
|
2021
Q4 | $640K | Buy |
8,810
+94
| +1% | +$6.47K | 0.07% | 213 |
|
|
2021
Q3 | $609K | Sell |
8,716
-989
| -10% | -$69.5K | 0.07% | 216 |
|
|
2021
Q2 | $668K | Buy |
9,705
+450
| +5% | +$30K | 0.07% | 197 |
|
|
2021
Q1 | $598K | Sell |
9,255
-1,139
| -11% | -$73.4K | 0.09% | 212 |
|
|
2020
Q4 | $606K | Sell |
10,394
-3,397
| -25% | -$205K | 0.11% | 162 |
|
|
2020
Q3 | $871K | Sell |
13,791
-875
| -6% | -$60.7K | 0.18% | 98 |
|
|
2020
Q2 | $999K | Buy |
14,666
+290
| +2% | +$22.2K | 0.21% | 91 |
|
|
2020
Q1 | $1.11M | Buy |
14,376
+1,044
| +8% | +$72.1K | 0.29% | 64 |
|
|
2019
Q4 | $903K | Buy |
13,332
+3,837
| +40% | +$250K | 0.21% | 89 |
|
|
2019
Q3 | $602K | Sell |
9,495
-109
| -1% | -$7.13K | 0.4% | 44 |
|
|
2019
Q2 | $649K | Buy |
9,604
+4,904
| +104% | +$323K | 0.5% | 36 |
|
|
2019
Q1 | $306K | Sell |
4,700
-5,892
| -56% | -$392K | 0.4% | 50 |
|
|
2018
Q4 | $663K | Sell |
10,592
-461
| -4% | -$32.2K | 0.63% | 37 |
|
|
2018
Q3 | $853K | Buy |
11,053
+96
| +0.9% | +$7.25K | 0.72% | 34 |
|
|
2018
Q2 | $776K | Sell |
10,957
-700
| -6% | -$49.4K | 0.7% | 33 |
|
|
2018
Q1 | $879K | Sell |
11,657
-157
| -1% | -$12.5K | 0.81% | 30 |
|
|
2017
Q4 | $846K | Sell |
11,814
-535
| -4% | -$40.6K | 0.77% | 29 |
|
|
2017
Q3 | $1M | Hold |
12,349
| – | – | 0.91% | 26 |
|
|
2017
Q2 | $875K | Buy |
+12,349
| New | +$822K | 0.56% | 46 |
|
|
2016
Q2 | – | Sell |
-18,393
| Closed | -$1.69M | – | 71 |
|
|
2016
Q1 | $1.69M | Buy |
+18,393
| New | +$1.66M | 1.84% | 6 |
|
Other funds holding GILD
VCM
VPM
Capital Asset Advisory Services's GILD Position: Q1 2026 in Review
Capital Asset Advisory Services increased its Gilead Sciences (GILD) stake by 3.5% in Q1 2026, buying an estimated $17.8K and bringing the position to 3,800 shares worth $516K. The position accounts for 0.02% of the portfolio, ranked #185.
Capital Asset Advisory Services first reported a position in GILD in Q1 2016 and has held it in 35 quarters since. The position peaked at $1.69M in Q1 2016. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.
- Capital Asset Advisory Services held 3,800 shares of Gilead Sciences worth $516K as of Q1 2026.
- Capital Asset Advisory Services bought 127 Gilead Sciences shares in Q1 2026, an estimated $17.8K.
- Gilead Sciences made up 0.02% of Capital Asset Advisory Services's portfolio in Q1 2026, its #185 holding.
- Capital Asset Advisory Services first reported a position in Gilead Sciences in Q1 2016 and has held it in 35 quarters since.
- Capital Asset Advisory Services's Gilead Sciences position peaked at $1.69M in Q1 2016.
- 2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.
Based on Capital Asset Advisory Services's 13F filing for Q1 2026, filed 24 Apr 2026.